Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Immune Thrombocytopenia (ITP): early-phase trial registry
3 of 3 indexed Immune Thrombocytopenia (ITP) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Immune Thrombocytopenia (ITP): 3 US clinical trials tracked, 3 recruiting.
Immune Thrombocytopenia (ITP) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Nuvig Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition immune-thrombocytopenia-itp
OPEN 3 | RECR 100% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Immune Thrombocytopenia (ITP) lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Immune Thrombocytopenia (ITP) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Immune Thrombocytopenia (ITP) is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Chugai Pharmaceutical
NCT06371417
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Eli Lilly and Company
NCT06721013
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
Nuvig Therapeutics
NCT07095127
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Immune Thrombocytopenia (ITP) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Immune Thrombocytopenia (ITP) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Immune Thrombocytopenia (ITP) page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Immune Thrombocytopenia (ITP) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nuvig Therapeutics sponsors the most Immune Thrombocytopenia (ITP) trials on record, review their full trial history before evaluating a specific study. See Nuvig Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Immune Thrombocytopenia (ITP) condition card totals 3 registered trials; most-linked intervention RAY121; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.